Healthcare Third-Party Risk Management: The Complete 2026 Guide for Health Systems, Pharma and Health Tech
Healthcare TPRM is the discipline of managing risks from vendors, suppliers and service providers in health sectors. It covers cybersecurity, HIPAA compliance, patient safety, financial crime and ESG simultaneously and it is materially different from TPRM in financial services.
What this guide covers: Healthcare TPRM (Third-Party Risk Management) is the structured process health systems, hospitals, pharmaceutical companies and health technology firms use to identify, assess and continuously monitor risks from external vendors, particularly those who access patient data, support clinical operations or supply regulated products. This guide covers HIPAA and BAA requirements, FDA and medical device obligations, the lessons from the 2024 Change Healthcare breach, the intelligence gap in questionnaire-only programmes, and how to build a programme that satisfies both regulatory obligations and patient safety requirements.
Table of Content:
Why healthcare is highest risk
Change Healthcare lessons
7 vendor types
Risk categories
HIPAA and BAA
Assessment process
The intelligence gap
FDA and medical devices
Build a programme
How Neotas helps
Case studies
FAQs
Last reviewed: May 2026 | Reading time: 20 minutes
of serious healthcare data breaches involve a third party
vendors connected to average hospital system
average cost of a healthcare vendor-related breach
Americans had data exposed in the 2024 Change Healthcare attack
What is Healthcare Third-Party Risk Management (TPRM)?
Healthcare TPRM (Third-Party Risk Management) is the structured process health systems, hospitals, pharmaceutical companies and health technology firms use to identify, assess and continuously monitor the risks created by external vendors, suppliers and service providers. It specifically covers vendors who access patient data, support clinical operations or supply regulated products. It spans cybersecurity, HIPAA compliance, FDA obligations, patient safety, reputational and financial crime risk simultaneously.
Healthcare third-party risk management is not purely a cybersecurity function. It is a clinical, regulatory and operational discipline that happens to have a cybersecurity component. When a pharmacy benefits manager fails, patients cannot access medication. When an EHR vendor suffers a breach, hospital revenue cycles collapse. When a medical device supplier is linked to sanctions exposure, the procurement team carries the liability.
Standard TPRM frameworks were built for financial services. Healthcare requires a different approach: one that accounts for patient safety, HIPAA’s Business Associate Agreement obligations, FDA supplier qualification requirements, and the clinical continuity stakes that make a failed vendor relationship far more consequential than a missed SLA.
The average hospital system works with more than 1,000 vendors simultaneously. HIPAA Journal, 2026 Every one of those relationships is a potential exposure point for patient data, clinical operations, regulatory compliance and the financial stability of the organisation itself.
Related: What is TPRM? Complete third-party risk management guide | Enhanced due diligence services | Vendor due diligence
Key takeaways
- Healthcare TPRM covers six distinct risk domains simultaneously: cybersecurity, regulatory compliance, patient safety, reputational, financial stability and ESG.
- The average hospital works with over 1,000 vendors. Each one is a potential exposure point for patient data and clinical operations.
- Healthcare TPRM is materially different from TPRM in financial services because vendor failure has direct patient safety consequences.
Why Healthcare Third-Party Risk Management is important?
In healthcare, third-party risk is rarely theoretical. A delayed pathology report, a compromised medical device vendor, or an outage in a cloud EHR platform can disrupt patient care within minutes. Across the US, UK, and global healthcare systems, hospitals are under pressure to strengthen oversight across sprawling vendor ecosystems that now include telehealth providers, AI platforms, billing partners, staffing agencies and connected medical technologies. Effective healthcare TPRM helps organisations prioritise vendors based on operational and clinical impact, reducing exposure across cybersecurity, compliance, patient safety and service continuity.
Why healthcare carries the highest third-party risk burden of any sector
Healthcare is the sector with the highest rate of third-party data breaches, the highest average breach cost and the most complex regulatory overlay of any industry. Three factors combine to create this exposure.
Patient safety dependency. A vendor failure in financial services disrupts transactions. A vendor failure in healthcare can disrupt care delivery, delay medication dispensing or take diagnostic equipment offline. The stakes are clinical, not just operational. When Change Healthcare’s systems went down in February 2024, pharmacists across the US could not process prescriptions for weeks. That is not a cybersecurity story. That is a vendor dependency story with patient safety consequences.
PHI sensitivity and regulatory obligation. Protected Health Information (PHI) is estimated to be worth significantly more on dark web markets than financial data. Healthcare IT News, 2024 Every vendor touching PHI creates a HIPAA liability for the covered entity, regardless of whether the vendor was directly at fault. The legal obligation for healthcare vendor risk management is not discretionary.
Dual regulatory burden. Healthcare vendors face simultaneous oversight from HIPAA and HITECH (patient data), FDA (medical devices and pharmaceutical supply chains), CMS Conditions of Participation (Medicare and Medicaid providers), and state-level health data privacy laws. Each framework imposes its own vendor management obligations. A programme that satisfies HIPAA may not satisfy FDA requirements for a medical device supplier. Both must be addressed.
Sector benchmark: 31% of cyber insurance claims in 2024 were linked to third-party vendor issues in healthcare. Breaches involving vendors cost an average of $4.88 million, significantly higher than internally caused breaches. Censinet, 2025
The counterintuitive reality of Healthcare Third-Party Risk Management:
Most healthcare organisations focus their third-party risk programmes almost entirely on cybersecurity assessment: questionnaires, security ratings and penetration testing.
What often goes unnoticed is the wider operational and integrity risk layer surrounding vendors and suppliers. Financial distress in a critical supplier, regulatory action against a pharmaceutical manufacturer, opaque beneficial ownership structures in a medical device distributor, or ESG failures within a clinical staffing partner can create serious downstream exposure long before a cyber incident occurs.
These are the risks that traditional questionnaire-led programmes rarely uncover. They are also the issues most likely to trigger operational disruption, regulatory scrutiny, reputational damage and patient safety concerns across modern healthcare systems.
Related: Healthcare supply chain risk management | Financial crime compliance in vendor relationships
Healthcare has the highest third-party breach rate, highest average breach cost and most complex regulatory overlay of any sector. Patient safety dependency, PHI sensitivity and dual regulatory burden combine to create a risk profile that standard TPRM frameworks were not designed for.
What the Change Healthcare breach changed for Healthcare Third-Party Risk Management
The February 2024 ransomware attack on Change Healthcare is the defining healthcare third-party risk event of the decade. Understanding what happened, why it happened and what it means for vendor risk programmes is now a baseline requirement for anyone building or reviewing a healthcare TPRM framework.
What happened
A ransomware group exploited compromised credentials to access Change Healthcare’s systems. The attack took down prescription processing for pharmacies across the United States, disrupted medical claims submissions and payment processing nationwide, and exposed the personal health data of approximately one in three Americans. Hospitals reported revenue declines of up to 17% in the weeks following the attack. Dallas Federal Reserve research, 2025
Why it was a TPRM failure, not just a cybersecurity failure
Change Healthcare was a known, critical vendor to thousands of healthcare organisations. Most had Business Associate Agreements in place. Many had security questionnaires on file. What they lacked was meaningful ongoing assessment of four specific risk factors that a mature TPRM programme would have surfaced:
- Concentration risk. A single vendor handled claims processing for an estimated 40% of US medical claims. No individual organisation could have eliminated their dependency, but a portfolio-level concentration assessment would have revealed the systemic exposure and triggered contingency planning.
- Fourth-party dependencies. Change Healthcare relied on sub-contractors and cloud infrastructure that created additional exposure points invisible to the covered entities relying on them. HITECH requires business associates to impose equivalent obligations on their sub-contractors. In practice, most BAAs do not verify this.
- Continuous monitoring failures. Security researchers had flagged concerns about Change Healthcare’s security posture in the months before the attack. Annual questionnaire-based reviews would not have captured this. Real-time adverse media and security posture monitoring would have.
- Vendor outage exposure. Most healthcare organisations had no tested contingency for claims processing disruption lasting more than 72 hours. This was not a security gap. It was an operational resilience gap that TPRM programmes should map explicitly.
- Ransomware propagation path. The attack spread because multi-factor authentication was not enforced on a legacy remote access portal. A comprehensive vendor assessment would have identified this. A self-certification questionnaire would not.
“The Change Healthcare event demonstrated that a single third-party failure can generate systemic healthcare disruption at national scale. The lesson is not to improve vendor questionnaires. The lesson is that questionnaire-based programmes are insufficient for critical vendor relationships.”
Dallas Federal Reserve research, 2025
What a mature Healthcare Third-Party Risk Management programme would have done differently
- Classified Change Healthcare as a Critical vendor with continuous monitoring obligations, not just annual review
- Conducted an independent security architecture review, rather than accepting a self-certified questionnaire
- Mapped concentration risk across the claims processing portfolio and developed tested contingency procedures
- Required contractual evidence of MFA enforcement and legacy system decommissioning timelines
- Monitored adverse media and security researcher disclosures in real time, not on an annual cycle
Related: TPRM lifecycle guide: continuous monitoring stage | Supply chain concentration risk management
The 2024 Change Healthcare breach exposed five structural failures in healthcare TPRM: concentration risk blindness, fourth-party dependency gaps, annual-only monitoring, missing contingency planning and over-reliance on self-certified questionnaires. A mature programme addresses all five.
The 7 categories of healthcare vendor and their risk profile
Healthcare organisations work with a wider range of vendor types than almost any other sector. Each category carries a distinct risk profile, regulatory obligation and due diligence requirement. Treating all vendors identically is the most common healthcare TPRM failure.
| Vendor type | Risk level | Key regulatory obligation | Primary risk if they fail |
|---|---|---|---|
| EHR and clinical software vendors | Critical | HIPAA BAA, SOC 2, NIST CSF | Mass PHI exposure and clinical operations disruption |
| Medical device manufacturers | Critical | FDA 21 CFR Part 820, ISO 13485, MDS2 | Patient safety event and data breach via connected devices |
| Cloud and SaaS providers | Critical | HIPAA BAA, SOC 2 Type II, ISO 27001 | Data breach and operational downtime |
| Revenue cycle and billing services | High | HIPAA BAA, PCI DSS | Financial fraud and PHI exposure and revenue disruption |
| Diagnostic labs and imaging providers | High | HIPAA BAA, CLIA | Clinical error and PHI exposure |
| Telehealth platforms | High | HIPAA BAA, FTC Health Breach Notification Rule | Real-time patient data breach and care disruption |
| Pharmaceutical and API suppliers | High | FDA GMP 21 CFR Part 211, ICH Q10, Modern Slavery Act (UK) | Drug safety event and ESG violation and supply disruption |
Related: Vendor due diligence services | Vendor due diligence questionnaire guide | Vendor due diligence report
Healthcare vendor risk is not uniform. EHR vendors, medical device manufacturers and cloud providers carrying PHI are Critical-tier and require the deepest due diligence. Each vendor type carries its own primary regulatory obligation: HIPAA BAA for PHI handlers, FDA 21 CFR for device manufacturers, CLIA for diagnostic labs.
The 6 risk categories in Healthcare Third-Party Risk Management
A complete healthcare vendor risk management programme addresses six distinct risk domains. Most programmes actively cover only the first one. The others are where the highest-value incidents originate.
Risk Category 1
Every vendor with access to systems containing PHI creates cybersecurity exposure. Assessment criteria include: SOC 2 Type II, ISO 27001, penetration test results within 12 months, incident response procedures, MFA enforcement and data residency. For connected medical devices: MDS2 attestation, software bill of materials (SBOM), patch management procedures and network segmentation evidence.
Risk Category 2
HIPAA violations carry fines of up to $1.9 million per violation category per year. HHS OCR, 2024 A vendor’s non-compliance event creates direct regulatory exposure for the covered entity even without direct involvement. Assessment criteria include regulatory status and licences, active HIPAA BAA, documented HIPAA training programme and record of OCR investigations or enforcement actions.
Risk Category 3
This category distinguishes healthcare TPRM from all other sectors. A failed EHR vendor or medical device supplier is not an IT incident. It is a patient safety event. Assessment criteria include business continuity planning, disaster recovery procedures and test results, SLA definitions and breach history, clinical dependency mapping and single points of failure identification. Concentration risk assessment is most critical here.
Risk Category 4
Standard database checks cannot surface newly emerging adverse media, foreign-language press coverage, or reputational risks that have not yet reached structured databases. A pharmaceutical supplier linked to bribery allegations in its manufacturing region creates reputational exposure for the health system procuring from it, regardless of whether the health system was aware. This is the gap that intelligence-led OSINT screening addresses. Assessment criteria include adverse media screening across 200 or more languages, PEP and sanctions screening for vendor executives, beneficial ownership verification and historical regulatory actions in any jurisdiction.
Risk Category 5
The Change Healthcare breach demonstrated what happens when a critical function depends on a single vendor with no viable alternative. Assessment criteria include audited financial statements for the previous two to three years, credit ratings, client concentration analysis, operational redundancy and concentration risk mapping across the vendor portfolio. Healthcare supply chain risk from pharmaceutical API sourcing concentration is a variant of this risk that most TPRM programmes do not assess.
Risk Category 6
This is the most underserved risk category in healthcare TPRM. NHS Supply Chain frameworks, pharmaceutical manufacturing labour practices, medical device component sourcing from sanctioned territories, and anti-bribery and corruption obligations in clinical procurement all create both regulatory and reputational exposure. UK healthcare organisations with turnover above £36 million have reporting obligations under the Modern Slavery Act 2015. legislation.gov.uk
Related: ESG due diligence services | Financial crime compliance | Supply chain risk management
Healthcare TPRM covers six risk categories: cybersecurity and PHI, regulatory compliance, patient safety and clinical continuity, reputational and adverse media, financial stability and concentration, and ESG and ethical supply chain. Most healthcare vendor risk programmes only actively address the first two. The others are where the most serious incidents originate.
HIPAA, HITECH and Business Associate Agreement requirements
Direct answer: HIPAA requires covered entities to conduct documented, risk-based due diligence on all Business Associates – any vendor that creates, receives, maintains or transmits Protected Health Information (PHI). A signed Business Associate Agreement (BAA) is mandatory before any PHI handling begins. HITECH extended these obligations to sub-contractors, making fourth-party PHI exposure a direct regulatory compliance requirement.
What a compliant Business Associate Agreement must contain
A BAA is the legal backbone of HIPAA compliance for any vendor relationship involving PHI. Every BAA must address the following provisions. Missing any one creates a direct HIPAA compliance gap:
- Permitted uses and disclosures of PHI – clearly defined, not open-ended
- Prohibition on unauthorised use or disclosure
- Minimum necessary standard – vendor accesses only the PHI required for the contracted function
- Appropriate safeguards – administrative, physical and technical controls specified
- Breach notification timeline – vendor must notify the covered entity without unreasonable delay and within 60 days of discovery; many organisations contractually require shorter timelines
- Sub-contractor obligations – under HITECH, the BAA must require the business associate to impose equivalent safeguards on any sub-contractor handling PHI
- HHS audit cooperation – vendor must make internal practices available to HHS for compliance review
- Termination and PHI return or destruction – at relationship end, PHI must be returned or securely destroyed with destruction documented
The sub-contractor gap: HITECH extended HIPAA obligations to business associates’ sub-contractors. In practice, most BAAs require the business associate to impose equivalent safeguards on sub-contractors. Very few covered entities actually verify this is happening. This is precisely the fourth-party risk gap that sophisticated healthcare TPRM programmes must close. The Change Healthcare breach exploited exactly this gap.
HIPAA regulatory requirements for vendor risk management
| Regulation | Applies to | Core vendor management obligation | Penalty for non-compliance |
|---|---|---|---|
| HIPAA Privacy Rule | All covered entities and BAs | BAA required before any PHI sharing; permitted uses defined | Up to $50,000 per violation, $1.9m annual cap per category |
| HIPAA Security Rule | All covered entities and BAs | Administrative, physical and technical safeguards verified at vendors handling ePHI | Same as Privacy Rule |
| HITECH Act | BAs and their sub-contractors | HIPAA obligations flow to sub-contractors; strengthened enforcement | Up to $1.9m per violation category per year |
| FDA 21 CFR Part 820 | Medical device manufacturers | Supplier qualification, quality agreements, incoming inspection, supplier audits | Warning letters, consent decrees, product recalls, criminal prosecution |
| CMS Conditions of Participation | Medicare and Medicaid participating providers | Information governance and patient safety requirements influence vendor selection | Loss of Medicare and Medicaid certification |
| Modern Slavery Act 2015 | UK organisations with £36m+ turnover | Annual supply chain transparency statement; active due diligence on supplier labour practices | Reputational consequences; court injunctions |
Related: Full TPRM regulatory requirements across DORA, FCA and OCC | TPRM policy guide
HIPAA and HITECH together require documented, ongoing, risk-based vendor due diligence for all Business Associates. A compliant BAA must cover permitted PHI uses, safeguards, breach notification timelines, sub-contractor obligations and HHS cooperation rights. HITECH extended these obligations to sub-contractors, making fourth-party risk a regulatory requirement rather than just good practice.
The healthcare vendor risk assessment process: 7 stages
Healthcare vendor risk management follows a structured lifecycle. The process is continuous and does not end at onboarding. For the full methodology, see the Neotas TPRM lifecycle guide.
| Stage | What happens | Healthcare-specific requirement | Most common failure point |
|---|---|---|---|
| 1. Vendor inventory | Map every vendor with PHI access, clinical system access or patient-critical supply chain role | Include all Business Associates and sub-contractors handling PHI under HITECH | Most hospitals find 30 to 50% more vendors than their records show |
| 2. Risk tiering | Classify by PHI access level, clinical criticality, regulatory category and concentration risk | BAA requirement determines minimum due diligence threshold; clinical criticality determines tier | Classifying by vendor category rather than actual function and data access |
| 3. Pre-onboarding due diligence | Tier-proportionate assessment before any PHI access begins | Critical vendors: intelligence-led full assessment. Standard vendors: questionnaire plus BAA verification | Relying entirely on self-completed questionnaires – cannot detect what vendors do not disclose |
| 4. BAA and contract controls | Signed BAA before any PHI handling; contract provisions for breach notification, audit rights, sub-contractor disclosure | BAA must satisfy all HIPAA required provisions; sub-contractor obligations must flow through | Generic BAA templates missing HITECH sub-contractor obligations or specific breach notification timelines |
| 5. Ongoing monitoring | Continuous monitoring for adverse media, regulatory actions, security incidents and financial distress signals | Annual questionnaire alone does not satisfy HIPAA’s ongoing due diligence requirement | Annual-only reviews – most incidents happen between review cycles |
| 6. Issue management | Defined escalation paths and response timelines when monitoring flags a risk | OCR examines issue management records during investigations – documented response trails are critical | No documented response process – alerts fire but no defined action path exists |
| 7. Offboarding | PHI return or certified destruction, access revocation, BAA termination, documented closeout | HIPAA requires documented PHI disposition at relationship end – verbal assurance is not compliant | Residual PHI access left active months after the relationship ends |
Related: Full TPRM lifecycle guide | TPRM questionnaire guide and limitations | Vendor due diligence services | Enhanced due diligence for healthcare vendors
Healthcare vendor risk management runs a 7-stage lifecycle: inventory, tiering, pre-onboarding due diligence, BAA and contract controls, ongoing monitoring, issue management and offboarding. The most common failures are undercounting vendors in inventory, relying on questionnaires alone at stage 3, and using annual-only reviews at stage 5.
The intelligence gap: what healthcare vendor questionnaires cannot find
Every guide in this space recommends vendor questionnaires. None of them acknowledges the fundamental structural limitation: a questionnaire only surfaces information the vendor is willing and able to disclose. It cannot detect what vendors do not know about themselves, and it cannot detect what vendors are unwilling to disclose.
In healthcare, the risks that questionnaires structurally miss are precisely the ones most likely to create serious incidents.
What questionnaire-only programmes miss in healthcare specifically
- Adverse media in non-English press. A pharmaceutical manufacturer with documented GMP violations in its home country press, a medical device distributor linked to bribery allegations in an emerging market, a clinical staffing agency with undisclosed labour practice violations. Structured databases capture this weeks or months after the fact, if at all.
- Beneficial ownership opacity. A healthcare SaaS vendor owned through multiple holding companies, one layer of which contains a party connected to a sanctioned individual. No questionnaire asks about the full beneficial ownership chain. OSINT investigation surfaces it.
- Financial distress signals. A pharmacy benefits manager in early financial difficulty that has not yet appeared in public filings. Adverse credit indicators, supplier payment delays, executive departures and debt covenant issues are visible through financial intelligence monitoring long before formal disclosure.
- Regulatory actions in other jurisdictions. A medical device manufacturer with an active FDA 483 observation in one product line that did not make it into their self-certification questionnaire response.
- Concentration risk in sub-contractor infrastructure. Two critical EHR vendors both relying on the same cloud infrastructure provider in the same region. Neither discloses this because it is considered proprietary. Network analysis surfaces the shared dependency.
- Executive-level integrity risks. A vendor’s senior leadership team with undisclosed connections to public officials a direct FCPA or UK Bribery Act risk for the health system if not detected.
The Change Healthcare parallel
Security researchers had raised concerns about Change Healthcare’s security architecture in the months before the February 2024 attack. This information was publicly available in open-source forums and security researcher publications. An annual questionnaire cycle would not have captured it. A continuous monitoring programme scanning for adverse media, security researcher disclosures and regulatory flags would have. This is precisely what intelligence-led healthcare TPRM is designed to do.
Neotas addresses this gap through OSINT-enhanced vendor screening, combining adverse media monitoring across 200 or more languages, beneficial ownership analysis, financial intelligence, sanctions proximity screening and social media monitoring. For healthcare organisations, this capability is most critical for Tier 1 vendors: EHR providers, medical device manufacturers, pharma supply chain partners and revenue cycle operators. See enhanced due diligence services and OSINT tools and techniques in vendor screening.
Healthcare vendor questionnaires cannot detect adverse media in foreign press, beneficial ownership opacity, emerging financial distress, multi-jurisdiction regulatory actions, sub-contractor concentration risk or executive-level integrity issues. These are the risks most likely to create serious healthcare TPRM failures. Intelligence-led OSINT screening closes these gaps.
FDA requirements and medical device supplier risk management
Medical device suppliers and pharmaceutical manufacturers operate under a separate regulatory framework from HIPAA-governed vendors. FDA oversight creates specific TPRM obligations that most general vendor risk management frameworks do not address.
FDA 21 CFR Part 820: medical device supplier qualification
FDA’s Quality System Regulation requires medical device manufacturers to implement documented supplier qualification and oversight processes. This includes supplier evaluation criteria, approved supplier lists, incoming inspection procedures, periodic supplier audits and quality agreements. For health systems procuring medical devices, a vendor’s FDA compliance status is itself a TPRM due diligence item. A device manufacturer operating under an FDA consent decree or with active 483 observations creates downstream risk for the healthcare organisation using their products.
ISO 13485:2016: medical device quality management
ISO 13485 is the international standard for medical device quality management systems. Certification requires documented supplier evaluation, risk-based purchasing controls and ongoing supplier performance monitoring. ISO 13485 certification is a minimum quality assurance threshold for assessing medical device suppliers. Certification alone does not substitute for active intelligence-led due diligence on the supplier’s regulatory standing and reputational profile.
MDS2 and software bills of materials for connected medical devices
Connected medical devices in clinical environments create simultaneous clinical risk and cyber risk. Two assessment tools apply specifically to this category:
- MDS2 (Manufacturer Disclosure Statement for Medical Device Security): A standardised form medical device manufacturers complete disclosing cybersecurity capabilities, data handling practices and network connectivity requirements. Requiring a current MDS2 from all connected device vendors is a healthcare-specific due diligence step that general TPRM frameworks do not include.
- Software Bill of Materials (SBOM): FDA’s 2023 medical device cybersecurity guidance requires manufacturers to provide an SBOM a complete inventory of software components in the device. This enables health systems to assess whether any component contains known vulnerabilities or relies on software from sanctioned entities.
Pharmaceutical supply chain risk
Pharmaceutical procurement creates a distinct supply chain risk profile. Active Pharmaceutical Ingredient (API) sourcing concentration where a generic drug’s API comes from a single manufacturing region creates both supply disruption risk and geopolitical or sanctions risk that standard vendor questionnaires do not assess. The FDA’s drug shortage data consistently shows that concentration in API manufacturing creates systemic vulnerability for the US pharmaceutical supply chain. FDA Drug Shortages database
For UK pharmaceutical organisations, the Modern Slavery Act 2015 requires annual supply chain transparency statements covering due diligence on labour practices across the supply chain, including API manufacturers and contract research organisations.
Related: Supply chain risk management services | ESG due diligence for pharmaceutical and healthcare supply chains
Section summary: Medical device suppliers require FDA 21 CFR Part 820 and ISO 13485 assessment alongside standard vendor risk checks. Connected devices require MDS2 attestation and SBOM review. Pharmaceutical supply chains require API sourcing assessment and, for UK organisations, Modern Slavery Act compliance verification across the supplier chain.
How to build a healthcare TPRM programme: 8 steps
Building a healthcare TPRM programme that satisfies HIPAA, FDA and clinical continuity requirements simultaneously requires a structured approach. The order matters. Most programmes fail by jumping to technology before governance and tiering exist. For a full implementation roadmap, see the Neotas TPRM framework guide.
- Define scope, ownership and governance. Assign ownership – typically a joint function between CISO, Chief Compliance Officer and General Counsel. Define what constitutes a vendor for your organisation, including BAs, sub-contractors, staffing agencies and clinical equipment suppliers. Get board-level sign-off on the programme charter.
- Build the vendor inventory. Use procurement records, accounts payable data, IT system access logs and clinical department interviews. Include all Business Associates and HITECH sub-contractors. Expect to find 30 to 50% more vendor relationships than your current records show.
- Design the healthcare-specific risk tiering model. Tier criteria must include: PHI access level, BAA requirement, clinical criticality, FDA regulatory category, concentration risk and jurisdictional exposure. Three tiers minimum: Critical, Important and Standard.
- Design due diligence processes by tier. Critical (Tier 1): full intelligence-led assessment covering all 6 risk categories. Important (Tier 2): structured questionnaire plus independent adverse media and financial screening. Standard (Tier 3): questionnaire plus BAA verification. No vendor handling PHI should fall below Tier 2.
- Build BAA and contract standards. Develop a compliant BAA template covering all HIPAA and HITECH required provisions. Establish minimum contractual provisions for non-BAA vendors: audit rights, breach notification, sub-contractor disclosure and exit assistance. See TPRM policy guide.
- Implement continuous monitoring for Tier 1 and 2 vendors. Annual questionnaires alone do not satisfy HIPAA’s ongoing due diligence requirement. Automate adverse media alerts, sanctions list changes and financial health signals. Define monitoring frequency: Critical vendors monthly or real-time; Standard vendors annually.
- Define issue management and escalation paths. Who receives monitoring alerts? What action is required? What triggers escalation to senior management or the board? Document this before the first alert fires. OCR investigations examine issue management records closely.
- Establish governance and reporting. Board-level reporting on TPRM programme status, key risk indicators and open issues. Maintain a vendor register accessible for OCR audits. Document the programme formally in a TPRM policy. See TPRM policy template.
Related: Third-party risk management framework guide | TPRM policy guide | TPRM maturity model
Building a healthcare TPRM programme requires 8 steps: define governance, build vendor inventory, design healthcare-specific risk tiering, design tier-proportionate due diligence, establish BAA and contract standards, implement continuous monitoring, define issue management and set governance reporting. Governance and tiering must come before technology.
How Neotas supports healthcare TPRM
Neotas is an intelligence-led third-party risk management provider, rated in the Chartis FCC50 as a leading financial crime compliance technology provider. Healthcare organisations use Neotas specifically for the intelligence layer that questionnaire platforms and cybersecurity rating tools cannot provide.
| Capability | Healthcare risk category addressed | What it delivers |
|---|---|---|
| Intelligence-led vendor due diligence | All 6 risk categories | OSINT-enhanced assessment covering cybersecurity, financial health, regulatory standing, adverse media, beneficial ownership and ESG indicators |
| Adverse media screening | Reputational and adverse media risk | 200+ languages, traditional press, social media and emerging sources surfaces risks weeks before structured database updates |
| Beneficial ownership analysis | Financial crime and reputational risk | Multi-layer corporate structure investigation to identify sanctions exposure, PEP connections and undisclosed conflicts of interest |
| Financial distress monitoring | Financial stability and concentration risk | Early warning signals from payment behaviour, credit indicators, executive departure patterns and regulatory filings – months before formal disclosure |
| ESG and ethical supply chain screening | ESG, Modern Slavery and ethical risk | Pharmaceutical API sourcing assessment, labour practice violation screening, ABAC indicators and UK Modern Slavery Act compliance evidence |
| Continuous monitoring | All categories ongoing | Automated alerts for adverse media, sanctions changes, regulatory actions and financial health signals closes the annual-review gap that the Change Healthcare incident exposed |
| Financial crime compliance integration | Regulatory and financial crime risk | AML, KYC and sanctions screening embedded in vendor due diligence, particularly relevant for pharmaceutical and medical device supply chains with complex international ownership structures |
Build a healthcare TPRM programme that goes beyond questionnaires
Neotas works with compliance leads, procurement directors and risk teams at health systems, pharmaceutical companies and health tech firms across the UK and US. We cover the intelligence layer that questionnaire-only programmes cannot reach.
Chartis FCC50 recognised. Used across healthcare, life sciences, insurance and financial services.
No commitment required. We will confirm availability within 1 working day.
Healthcare TPRM in practice: what intelligence-led screening found
Each of the following engagements involved a vendor that looked clean on standard database checks. Intelligence-led screening found the risk before it became the client’s problem.
Supply chain risk identified before contract signature
A healthcare procurement team needed supply chain due diligence beyond standard database checks on a prospective pharmaceutical partner. OSINT screening surfaced adverse media, undisclosed regulatory actions and reputational risk indicators invisible to structured data sources. The engagement prevented a high-value partnership with a materially compromised supplier. Read the supply chain OSINT case study
ESG screening uncovers vendor supply chain exposure
A global organisation commissioned ESG risk screening on its vendor population. Labour practice violations and environmental breaches were identified in a Tier 2 supplier – the kind of sub-contractor visibility that TPRM programmes must now demonstrate under Modern Slavery Act and corporate sustainability due diligence obligations. Read the ESG supply chain case study
Third-party risk found through OSINT
A regulated organisation needed vendor due diligence beyond questionnaire-based assessment. Neotas OSINT screening surfaced adverse media, undisclosed corporate connections and reputational red flags that structured data sources had missed entirely. Read the full TPRM OSINT case study
Network analysis uncovers beneficial ownership risk
Standard corporate checks on a procurement counterparty returned clean results. Neotas network analysis mapped undisclosed corporate relationships that created material risk exposure – the beneficial ownership opacity issue that affects pharmaceutical and medical device supply chain due diligence directly. Read the network analysis case study
